Skip to main content

Advertisement

Log in

Comprehensive analysis of ALK, ROS1 and RET rearrangements in locally advanced rectal cancer

Journal of Genetics Aims and scope Submit manuscript

Abstract

Gene rearrangements, such as anaplastic lymphoma kinase (ALK), c-ros oncogene 1 receptor tyrosine kinase (ROS1), rearranged during transfection (RET) and neurotrophic receptor tyrosine kinase 1 (NTRK1), identified in cancer have been indicated to be robust therapeutic targets in lung carcinomas. However, a few studies have focussed on locally advanced rectal cancer (LARC). The discovery of novel gene fusions is also valuable for LARC research. We used mass spectrometry-based assays and RNA sequencing to detect both known ALK, ROS1, RET and NTRK1 rearrangements and novel gene fusions in LARC patients. FusionMap was also used to find gene fusions. None of the ALK, ROS1, RET or NTRK1 gene fusions were detected by mass spectrometry-based assays or RNA sequencing. Three fusion candidates, integrin subunit beta 7 (ITGB7)-ROS1, lamin A/C (LMNA)-NTRK1 and Golgi-associated PDZ and coiled-coil motif containing (GOPC)-keratin 8 (KRT8), showed relatively high junction-spanning reads by the FusionMap algorithm, but did not pass validation. These results suggest that no ALK, ROS1 or RET rearrangements were found in LARC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  • Amatu A., Somaschini A., Cerea G., Bosotti R., Valtorta E., Buonandi P. et al. 2015 Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br. J. Cancer 113, 1730–1734.

    Article  CAS  Google Scholar 

  • Annala M. J., Parker B. C., Zhang W. and Nykter M. 2013 Fusion genes and their discovery using high throughput sequencing. Cancer Lett. 340, 192–200.

    Article  CAS  Google Scholar 

  • Cabillic F., Gros A., Dugay F., Begueret H., Mesturoux L., Chiforeanu D. C. et al. 2014 Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J. Thorac. Oncol. 9, 295–306.

    Article  CAS  Google Scholar 

  • Choi Y., Kwon C. H., Lee S. J., Park J., Shin J. Y. and Park D. Y. 2018 Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer. Br. J. Cancer 119, 230–240.

    Article  CAS  Google Scholar 

  • Cocco E., Scaltriti M. and Drilon A. 2018 NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 15, 731–747.

    Article  CAS  Google Scholar 

  • Coustan-Smith E., Song G., Clark C., Key L., Liu P., Mehrpooya M. et al. 2011 New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 117, 6267–6276.

    Article  CAS  Google Scholar 

  • Davies K. D., Le A. T., Theodoro M. F., Skokan M. C., Aisner D. L., Berge E. M. et al. 2012 Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin. Cancer Res. 18, 4570–4579.

    Article  CAS  Google Scholar 

  • Farago A. F and Azzoli C. G. 2017 Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. Transl. Lung Cancer Res. 6, 550–559.

    Article  CAS  Google Scholar 

  • Ge H., Liu K., Juan T., Fang F., Newman M. and Hoeck W. 2011 FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution. Bioinformatics 27, 1922–1928.

    Article  CAS  Google Scholar 

  • Goldman J. M. and Melo J. V. 2003 Chronic myeloid leukemia—advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451–1464.

    Article  CAS  Google Scholar 

  • Julien L. A and Thorson A. G. 2010 Current neoadjuvant strategies in rectal cancer. J. Surg. Oncol. 101, 321–326.

    Article  CAS  Google Scholar 

  • Le Rolle A. F., Klempner S. J., Garrett C. R., Seery T., Sanford E. M, Balasubramanian S. et al. 2015 Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget 6, 28929–28937.

    Article  Google Scholar 

  • Lee S. J., Li G. G., Kim S. T., Hong M. E., Jang J., Yoon N. et al. 2015 NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Oncotarget 6, 39028–39035.

    Article  Google Scholar 

  • Lipson D., Capelletti M., Yelensky R., Otto G., Parker A., Jarosz M. et al. 2012 Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382–384.

    Article  CAS  Google Scholar 

  • Luo W., Liao W-J., Ma L., Huang Y.-T., Shi M., Wen Q. et al. 2010 Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin. Cancer Immunol. Immunother. CII 59, 247–256.

    Article  CAS  Google Scholar 

  • Mandard A. M., Dalibard F., Mandard J. C., Marnay J., Henry-Amar M., Petiot J. F. et al. 1994 Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73, 2680–2686.

    Article  CAS  Google Scholar 

  • Ohara N., Haraguchi N., Koseki J., Nishizawa Y., Kawai K., Takahashi H. et al. 2017 Low expression of the GOPC is a poor prognostic marker in colorectal cancer. Oncol. Lett. 14, 4483–4490.

    Article  Google Scholar 

  • Ozsolak F. and Milos P. M. 2011 RNA sequencing: Advances, challenges and opportunities. Nat. Rev. Genet. 12, 87–98.

    Article  CAS  Google Scholar 

  • Park D. Y., Choi C., Shin E., Lee J. H., Kwon C. H., Jo H. J. et al. 2016 NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer. Oncotarget 7, 8399–8412.

    Article  Google Scholar 

  • Rogers T. M., Arnau G. M., Ryland G. L., Huang S., Lira M. E., Emmanuel Y. et al. 2017 Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci. Rep. 7, 42259.

    Article  CAS  Google Scholar 

  • Sakai K., Okamoto I., Takezawa K., Hirashima T., Kaneda H., Takeda M. et al.. 2012 A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer. J. Thorac. Oncol. 7, 913–918.

    Article  CAS  Google Scholar 

  • Sartore-Bianchi A., Ardini E., Bosotti R., Amatu A., Valtorta E., Somaschini A. et al. 2016 Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. J. Natl. Cancer Inst. 108, djv306.

    Article  Google Scholar 

  • Shiroguchi K., Jia T. Z., Sims P. A. and Xie X. S. 2012 Digital RNA sequencing minimizes sequence-dependent bias and amplification noise with optimized single-molecule barcodes. Proc. Natl. Acad. Sci. USA 109, 1347–1352.

    Article  CAS  Google Scholar 

  • Stransky N., Cerami E., Schalm S., Kim J. L. and Lengauer C. 2014 The landscape of kinase fusions in cancer. Nat. Commun. 5, 4846.

    Article  CAS  Google Scholar 

  • Suehara Y., Arcila M., Wang L., Hasanovic A., Ang D., Ito T. et al. 2012 Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin. Cancer Res. 18, 6599–6608.

    Article  CAS  Google Scholar 

  • Takeuchi K., Soda M., Togashi Y., Suzuki R., Sakata S., Hatano S. et al. 2012 RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18, 378–381.

    Article  CAS  Google Scholar 

  • Tan H. S., Jiang W. H., He Y., Wang D. S., Wu Z. J., Wu D. S. et al. 2017 KRT8 upregulation promotes tumor metastasis and is predictive of a poor prognosis in clear cell renal cell carcinoma. Oncotarget. 8, 76189–76203.

    Article  Google Scholar 

  • Vaishnavi A., Capelletti M., Le A. T., Kako S., Butaney M., Ercan D. et al. 2013 Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat. Med. 19, 1469–1472.

    Article  CAS  Google Scholar 

  • Zeng L., Yang N. and Zhang Y. 2018 GOPC-ROS1 Rearrangement as an acquired resistance mechanism to osimertinib and responding to crizotinib combined treatments in lung adenocarcinoma. J. Thorac. Oncol. 13, e114–e116.

    Article  Google Scholar 

  • Zhou N., Schafer R., Li T., Fang M. and Liu L. 2018 A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report. BMC Cancer 18, 842.

    Article  Google Scholar 

Download references

Acknowledgements

This study was funded by the Industry-university-research Collaborative Innovation Major Projects of Guangzhou Science and Technology Planning Project, China (grant no. 201508020052). This manuscript has been revised by a native English speaker to effectively communicate to a professional medical audience.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Weiwen Xu.

Additional information

Corresponding editor: Indrajit Nanda

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, C., Li, M., Guo, Z. et al. Comprehensive analysis of ALK, ROS1 and RET rearrangements in locally advanced rectal cancer. J Genet 99, 78 (2020). https://doi.org/10.1007/s12041-020-01239-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12041-020-01239-1

Keywords

Navigation